Über uns

HPR Dr. Schaffler GmbH – a Contract Research Organization (CRO) – has built a successful name in pharmacodynamic research since 1976. This year HPR (Human Pharmacodynamic Research) opened a new business location in Aschheim-Dornach in the vicinity of Munich, Germany. Since more than 34 years, the founder of Human Pharmacodynamic Research, Dr. med. Klaus Schaffler (MD), has been specializing in the electrophysiology and pharmacology of the human central nervous system (CNS) – as well as in the field of human pain research. During this development process, HPR Dr. Schaffler GmbH has issued over 170 publications and has conducted more than 150 phase-1 studies with quite different objectives.

The CRO HPR is focused on Phase-1 clinical trials in human pharmacodynamics & in combined pd/pk approaches for national and international pharmaceutical companies. Hereby, HPR has elaborated a special model – the “Laser-Pain-Algesimetry” – under consideration of different sensitized and non-sensitized states of the skin (e.g. normal, UV and capsaicin skin) to examine & analyze the effect of analgesic and anti-inflammatory compounds in humans. This well-developed and -validated method of pain measurement guarantees a highly objective & quantitative approach to examine the efficacy of analgesics by examining brain responses to repetitive nociceptive stimuli via “Evoked Potentials” – recorded on-line in real-time from EEG. This strong, unique and systematic methodological feature of HPR Dr. Schaffler GmbH, together with flexible & creative study designs, as well as quick statistical data analysis and reporting, enables Human Pharmacodynamic Research (HPR) to provide customers with outstanding examination and analysis of medication effects on CNS and pain processing – also based on an existing large data base of prior investigated analgesics in different compound groups and also based on a large scale of experimental and practical trial experience and competence in this field.